As on Wednesday, Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) got off with the flyer as it spiked 18.46% to $26.7, before settling in for the price of $22.54 at the close. Taking a more long-term approach, CNTA posted a 52-week range of $9.60-$25.42.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -210.04%. Meanwhile, its Annual Earning per share during the time was -210.04%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 32.92%. This publicly-traded company’s shares outstanding now amounts to $134.42 million, simultaneously with a float of $85.46 million. The organization now has a market capitalization sitting at $3.59 billion. At the time of writing, stock’s 50-day Moving Average stood at $22.73, while the 200-day Moving Average is $16.76.
Centessa Pharmaceuticals plc ADR (CNTA) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Centessa Pharmaceuticals plc ADR’s current insider ownership accounts for 36.42%, in contrast to 57.02% institutional ownership. Preceding that transaction, on Oct 27 ’25, Company’s President, Orexin Program sold 8,000 for 25.00, making the whole transaction’s value amount to 200,000. This particular insider is now the holder of 194,394 in total.
Centessa Pharmaceuticals plc ADR (CNTA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
Centessa Pharmaceuticals plc ADR’s EPS increase for this current 12-month fiscal period is 32.92% and is forecasted to reach -1.61 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 5.20% through the next 5 years, which can be compared against the -210.04% growth it accomplished over the previous five years trading on the market.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
Let’s observe the current performance indicators for Centessa Pharmaceuticals plc ADR (CNTA). It’s Quick Ratio in the last reported quarter now stands at 10.57. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 238.31.
In the same vein, CNTA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.82, a figure that is expected to reach -0.39 in the next quarter, and analysts are predicting that it will be -1.61 at the market close of one year from today.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Through scrutinizing the latest numbers posted by the [Centessa Pharmaceuticals plc ADR, CNTA], it can be observed that its last 5-days Average volume of 2.85 million was better the volume of 1.09 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 74.65% While, its Average True Range was 72.10.
Raw Stochastic average of Centessa Pharmaceuticals plc ADR (CNTA) in the period of the previous 100 days is set at 96.68%, which indicates a major rise in contrast to 95.26% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 1.88 that was higher than 1.05 volatility it exhibited in the past 100-days period.
